Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II adaptive platform trial of NME combinations for functional cure of chronic hepatitis B
2019-002086-35Phase 2Unknown
- Sponsor
- Roche
- Start
- Dec 2019
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ruzotolimod, linvencorvir, xalnesiran, entecavir, tenofovir disoproxil fumarate and 2 more in Chronic Hepatitis B (CHB) (4 arms), sponsored by Roche. Primary endpoint: HBsAg loss at 24 weeks post-end of treatment. Status: unknown.
02
Drugs
ruzotolimodlinvencorvirxalnesiranentecavirtenofovir disoproxil fumarate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2019-002086-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002086-35.